Biohaven Ltd
BHVN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.17B
Close$
$-0.45
104.2% downside
Current Fair Value
104.2% downsideOvervalued by 104.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.17 Billion |
|---|---|
| Enterprise Value | $1.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.86 |
| Beta | 3.31 |
| Outstanding Shares | 147,615,197 |
Return
| Return on Equity | -500.14% |
|---|---|
| Return on Assets | -138.87% |
| Return on Invested Capital | -159.43% |
Valuation & Multiples
| P/E Ratio | -2.51 |
|---|---|
| PEG | 6.1 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.78 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 2.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.86
Average shareholder expectationRevenue Estimate
$267,436
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.76
Average shareholder expectationRevenue Estimate
$490,492
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2550▼ 25.61% |
|---|---|
| Total Calls | 2,049,606▼ 61.09% |
| Total Puts | 522,600▼ 80.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.12%▲ 3.36% |
|---|---|
| Total Invested | $1.20B▼ 12.40% |
| Investors Holding | 290▼ 10.00% |
ESG Score
No data
About Biohaven Pharmaceutical Holding Company Ltd
CEO: Vlad Coric